Showing results (321-330 of 340) with videos related to
Sort By:
Pageof 34
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.Diabetes, Obesity & Metabolism|May 2, 2022
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE studySatoshi Miyamoto, Hiddo J L Heerspink, Dick de Zeeuw, et al.Diabetes & Metabolism|February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trialJinlan Liao, Amy Kang, Chao Xia, et al.Journal of the American Society of Nephrology : JASN|May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized TrialMeg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary AnalysisMeg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.Kidney International Reports|March 30, 2026
Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONESatoshi Miyamoto, Hiddo J L Heerspink, Dick de Zeeuw, et al.Clinical Journal of the American Society of Nephrology : CJASN|April 8, 2020
Discontinuation of RAAS Inhibition in Children with Advanced CKDSophie M van den Belt, Hiddo J L Heerspink, Marietta Kirchner, et al.Pageof 34